Eli Lilly

AdaptHealth Corp. Appoints David S. Williams III to Board of Directors

Thursday, July 30, 2020 - 11:00am

AdaptHealth Corp. (NASDAQ: AHCO) (AdaptHealth), a leading provider of home medical equipment, supplies and related services in the United States, announced today the appointment of digital health executive and innovator David S. Williams III to the Companys Board of Directors.

Key Points: 
  • AdaptHealth Corp. (NASDAQ: AHCO) (AdaptHealth), a leading provider of home medical equipment, supplies and related services in the United States, announced today the appointment of digital health executive and innovator David S. Williams III to the Companys Board of Directors.
  • Williams began his career as an executive in the consulting and pharmaceutical industries, including Deloitte and Eli Lilly and Company.
  • Williams also serves on the board of directors of the Price Center for Entrepreneurship & Innovation at UCLA.
  • It is an honor to join the board of AdaptHealth at this exciting time in its development, said Mr. Williams.

AZTherapies Strengthens Board of Directors & Business Advisory Board with New Appointments

Wednesday, July 22, 2020 - 1:35pm

Flowers & Co. join BOD

Key Points: 
  • Flowers & Co. join BOD
    Retired Eli Lilly executive Joseph B. Kelley joins Business Advisory Board
    BOSTON, July 22, 2020 (GLOBE NEWSWIRE) -- AZTherapies, Inc. , a biopharmaceutical company in advanced clinical trials to treat neuroinflammatory diseases, today announced the appointment of three prominent business leaders to its Board of Directors and Business Advisory Board: Noah Gottdiener, Chief Executive Officer and Chairman of Duff & Phelps, a global corporate advisory firm, and Thierry Port, Managing Director of J.C.
  • Flowers & Co., a global private equity firm, have been appointed to the AZTherapies Board of Directors, and Joseph B Kelley, former Head of Global Government & International Corporate Affairs at Eli Lilly and Company, has joined the AZTherapies Business Advisory Board.
  • He currently serves as a senior advisor to life science company management teams and boards of directors.
  • from the University of Massachusetts Amherst in Business Management and Agriculture, Forestry & Plant Pathology, and completed an Executive Development Intensive in Business Administration & Management at Harvard Business School.

Lilly Confirms Date and Conference Call for Second-Quarter 2020 Financial Results Announcement

Friday, July 17, 2020 - 7:00pm

INDIANAPOLIS, July 17, 2020 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2020 financial results on Thursday, July 30, 2020.

Key Points: 
  • INDIANAPOLIS, July 17, 2020 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2020 financial results on Thursday, July 30, 2020.
  • Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.
  • The conference call will begin at 9 a.m. Eastern time.
  • Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world.

Eli Lilly and Company Foundation Pledges $25 Million to Combat Racial Injustice

Saturday, June 13, 2020 - 4:00pm

INDIANAPOLIS, June 13, 2020 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) and the Lilly Foundation announced today a pledge of $25 million and 25,000 volunteer hours over five years to decrease the burden of racial injustice and its effects on local and national communities of color.

Key Points: 
  • INDIANAPOLIS, June 13, 2020 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) and the Lilly Foundation announced today a pledge of $25 million and 25,000 volunteer hours over five years to decrease the burden of racial injustice and its effects on local and national communities of color.
  • "Lilly and the Lilly Foundation have a long history of standing beside our neighbors and communities," said Tiffany Benjamin, president of the Lilly Foundation.
  • The Lilly Foundation's financial commitment over five years will help develop and support effective solutions to racial inequity and social injustice primarily in Indianapolis, its surrounding counties and nationally.
  • "This is personal for me and for the whole company," said David Ricks, Lilly chairman and CEO.

Evox Therapeutics Announces a Multi-target RNAi and Antisense Research Collaboration and License Agreement With Lilly

Tuesday, June 9, 2020 - 12:00pm

OXFORD, England, June 9, 2020 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, is pleased to announce a research collaboration and license agreement with Eli Lilly and Company to leverage Evox's proprietary DeliverEXplatform to develop and deliver RNA interference (RNAi) & antisense oligonucleotide (ASO) drug payloads for the potential treatment of neurological disorders.

Key Points: 
  • OXFORD, England, June 9, 2020 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, is pleased to announce a research collaboration and license agreement with Eli Lilly and Company to leverage Evox's proprietary DeliverEXplatform to develop and deliver RNA interference (RNAi) & antisense oligonucleotide (ASO) drug payloads for the potential treatment of neurological disorders.
  • During this research collaboration and five-target license agreement, Evox will be responsible for exosome engineering in order to achieve brain/CNS-targeting, drug loading and analytics and some in vitro assay development, as well as material supply for initial in vivo studies.
  • Any resulting candidate handover and technology transfer to Lilly will occur after pre-clinical proof of concept studies have been completed.
  • Under the terms of the agreement, Evox will receive a $20 million cash up-front payment, research funding over three years, as well as a $10 million investment from Lilly in exchange for a convertible bond from the Company.

Lilly to Participate in Goldman Sachs Global Healthcare Conference

Monday, June 8, 2020 - 4:00pm

INDIANAPOLIS, June 8, 2020 /PRNewswire/ --Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10, 2020.

Key Points: 
  • INDIANAPOLIS, June 8, 2020 /PRNewswire/ --Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10, 2020.
  • Joshua Smiley, senior vice president and Lilly's chief financial officer, will participate in a virtual fireside chat at 2:10 p.m. EDT.
  • A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's investor website at https://investor.lilly.com/webcasts-and-presentations .
  • Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world.

Less Than One Year Post Launch, AbbVie's Rinvoq Disrupts the Rheumatoid Arthritis Treatment Landscape, While a Rich Pipeline Waits in the Wings

Friday, June 5, 2020 - 12:00am

Approved in 2012, Xeljanz enjoyed the "only JAK inhibitor" status for six years until Eli Lilly's Olumiant was approved.

Key Points: 
  • Approved in 2012, Xeljanz enjoyed the "only JAK inhibitor" status for six years until Eli Lilly's Olumiant was approved.
  • Where Olumiant faced challenges with regulatory delays and ultimately a less than desirable product label, Rinvoq came out of the gates strong.
  • AbbVie's SELECT-COMPARE trial, demonstrating Rinvoq's superiority over Humira, appears to be giving Rinvoq an advantage over existing JAK inhibitors, Xeljanz and Olumiant.
  • Indeed, this rich pipeline is poised to continue transforming the advanced systemic treatment landscape over the coming years.

Vaxcyte Appoints Halley E. Gilbert to Board of Directors

Wednesday, June 3, 2020 - 1:30pm

Were excited to welcome Halley to Vaxcytes board of directors, said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte.

Key Points: 
  • Were excited to welcome Halley to Vaxcytes board of directors, said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte.
  • In this capacity, Ms. Gilbert oversaw corporate and business development, legal, compliance and government affairs.
  • Ms. Gilbert currently also serves on the boards of directors of Arcutis Biotherapeutics, a medical dermatology company, and CytomX Therapeutics, a life sciences company.
  • She previously served on the board of directors of Dermira, Inc., a medical dermatology company (acquired by Eli Lilly and Company), and Achaogen, Inc., a biopharmaceutical company.

Statement from Lilly Chairman and CEO Dave Ricks on New Part D Senior Savings Model

Tuesday, May 26, 2020 - 10:51pm

David A. Ricks, Eli Lilly and Company (NYSE: LLY) Chairman and CEO, attended the announcement at the White House.

Key Points: 
  • David A. Ricks, Eli Lilly and Company (NYSE: LLY) Chairman and CEO, attended the announcement at the White House.
  • This new Part D Senior Savings Model is a natural fit with our other programs that can be found through the Lilly Diabetes Solution Center.
  • We are now able to provide the same opportunity for seniors who enroll in participating Medicare Part D plans.
  • People with questions about the Lilly Insulin Value Program and other solutions offered on Lilly insulins can dial the Lilly Diabetes Solution Center at (833) 808-1234.

AbCellera Announces Multi-Year Antibody Discovery Collaboration with Lilly

Friday, May 22, 2020 - 10:28pm

AbCellera announced today that it has entered into a multi-year strategic research collaboration and license agreement with Eli Lilly and Company (Lilly) on the discovery of antibodies for up to nine Lilly-selected therapeutic targets.

Key Points: 
  • AbCellera announced today that it has entered into a multi-year strategic research collaboration and license agreement with Eli Lilly and Company (Lilly) on the discovery of antibodies for up to nine Lilly-selected therapeutic targets.
  • AbCellera and Lilly were in discussions about the multi-target agreement in early 2020 when the COVID-19 pandemic emerged.
  • The companies worked quickly to focus the initial scope of the collaboration on creating antibody therapeutics for the possible prevention and treatment of COVID-19.
  • Lilly chose to partner with AbCellera because of their novel technology platform, and it has enabled the rapid identification of lead antibody candidates for our COVID-19 efforts.